Raymond E. Cabillot Sells 1,879 Shares of Pro-Dex, Inc. (NASDAQ:PDEX) Stock

Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot sold 1,879 shares of the stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $45.18, for a total value of $84,893.22. Following the transaction, the director now owns 352,996 shares in the company, valued at $15,948,359.28. This trade represents a 0.53 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Pro-Dex Stock Up 0.7 %

PDEX opened at $45.30 on Thursday. Pro-Dex, Inc. has a 12 month low of $16.18 and a 12 month high of $59.60. The company has a current ratio of 3.41, a quick ratio of 1.94 and a debt-to-equity ratio of 0.36. The business’s 50-day moving average price is $48.12 and its 200-day moving average price is $32.49. The company has a market cap of $147.68 million, a P/E ratio of 29.42 and a beta of 0.56.

Hedge Funds Weigh In On Pro-Dex

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Renaissance Technologies LLC boosted its stake in shares of Pro-Dex by 7.9% during the second quarter. Renaissance Technologies LLC now owns 12,240 shares of the medical instruments supplier’s stock valued at $240,000 after purchasing an additional 900 shares during the period. FMR LLC raised its holdings in Pro-Dex by 34.9% during the 3rd quarter. FMR LLC now owns 3,973 shares of the medical instruments supplier’s stock valued at $119,000 after buying an additional 1,028 shares during the last quarter. Geode Capital Management LLC boosted its position in Pro-Dex by 9.1% during the 3rd quarter. Geode Capital Management LLC now owns 27,435 shares of the medical instruments supplier’s stock valued at $819,000 after buying an additional 2,296 shares during the period. Dimensional Fund Advisors LP grew its holdings in Pro-Dex by 5.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 63,036 shares of the medical instruments supplier’s stock worth $1,238,000 after acquiring an additional 3,067 shares during the last quarter. Finally, Bard Associates Inc. increased its position in shares of Pro-Dex by 17.6% in the third quarter. Bard Associates Inc. now owns 13,596 shares of the medical instruments supplier’s stock valued at $406,000 after acquiring an additional 2,031 shares during the period. 15.28% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts have commented on the stock. Ascendiant Capital Markets increased their price target on shares of Pro-Dex from $30.00 to $52.00 and gave the company a “buy” rating in a research report on Monday, November 11th. StockNews.com raised shares of Pro-Dex from a “buy” rating to a “strong-buy” rating in a report on Saturday, December 14th.

About Pro-Dex

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.